Study title: Cytosine arabinoside (NSC-63878) and Daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia - Yates, J. W., Wallace, H. J., Ellison, R. R., Holland, J. F. - 1973 (Cancer Chemotherapy Rep. Part 1 Vol. 57 No. 4, 485 - 488) - Publication in the dos. Allemand jan 1981 -Cytosine arabinoside (NSC-63878) and Daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia - Yates, J. W., Wallace, H. J., Ellison, R. R., Holland, J. F. - 1973 (Cancer Chemotherapy Rep. Part 1 Vol. 57 No. 4, 485 - 488) - Publication in the dos. Allemand jan 1981 -
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: DAUNORUBICIN | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |